Andrew Lane, MD, PhD, of Dana Farber Cancer Institute, reports the results from a phase 2 trial in tagraxofusp, azacitidine, and venetoclax (TAG-AZA-VEN) triplet therapy in blastic plasmacytoid dendritic cell neoplasms in this video filmed at the 67th American Society of Hematology Annual Meeting and Exposition held in Orlando, Florida, in December 2025.
“Triplet therapy with TAG-AZA-VEN is effective and feasible in patients with previously untreated or R/R BPDCN, including in an older patient population,” the authors wrote. “The safety profile is consistent with prior studies of TAG and AZA/VEN. These data support TAG-AZA-VEN as an effective treatment option for patients with BPDCN.
